Home > Boards > US Listed > Biotechs >

CytomX Therapeutics, Inc. (CTMX)

CTMX RSS Feed
Add CTMX Price Alert      Hide Sticky   Hide Intro
Moderator: puravida
Search This Board: 
Last Post: 5/15/2019 6:03:32 PM - Followers: 7 - Board type: Free - Posts Today: 0

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition, it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., ImmunoGen, Inc., and The University of Texas M. D. Anderson Cancer Center to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.
CTMX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CTMX News: CytomX Therapeutics Announces Presentations at 2019 ASCO Annual Meeting 05/15/2019 05:20:00 PM
CTMX News: Amended Statement of Changes in Beneficial Ownership (4/a) 05/10/2019 12:28:05 PM
CTMX News: Current Report Filing (8-k) 05/09/2019 04:16:54 PM
CTMX News: Quarterly Report (10-q) 05/09/2019 04:13:53 PM
CTMX News: CytomX Therapeutics Announces First Quarter 2019 Financial Results 05/09/2019 04:10:00 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#27   Here's their ASCO abstract released tonight at 5pm puravida 05/15/19 06:03:32 PM
#26   CTMX presenting at Bank of America Merrill Lynch puravida 05/07/19 08:34:19 AM
#25   CytomX Therapeutics Appoints Elaine V. Jones, Ph.D., to puravida 05/01/19 10:24:07 AM
#24   ASCO 2019 titles released. PROCLAIM CX-072 results puravida 04/17/19 01:00:26 PM
#23   PROCLAIM-CX-2009 Dose Escalation Study Demonstrates Anti-Tumor Activity in puravida 04/02/19 01:15:25 PM
#22   - Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding puravida 03/29/19 03:15:10 PM
#21   'Yet there is an "over-focus" on Bristol-Myers Squibb's puravida 03/24/19 04:45:54 PM
#20   Title: A Probody Drug Conjugate Targeting CD166 (ALCAM) puravida 03/13/19 01:18:29 PM
#19   Title: CD166-DM4 Probody™ Drug Conjugate (CX-2009) Treatment of puravida 03/13/19 01:14:10 PM
#18   Here are the three AACR titles for CytomX. puravida 03/13/19 01:12:03 PM
#17   Current Events Synopsis for those who want to puravida 03/01/19 03:46:42 PM
#16   One thing is for sure, choosing to dump puravida 03/01/19 02:58:02 PM
#15   CEO deferred a question to upcoming AACR presentation puravida 03/01/19 02:52:01 PM
#14   yeah I'm impressed they have such a robust puravida 03/01/19 02:42:12 PM
#13   I think the cash on hand and large Dogoangel 02/28/19 08:15:19 PM
#12   Partner woes continue for CTMX. . puravida 02/28/19 12:14:25 PM
#11   PFE dumps CTMX collaboration: #msg-139113088. DewDiligence 03/07/18 06:09:06 PM
#10   Has this company any drugs in the market? manisero66 03/03/18 12:20:40 PM
#9   $CTMX entering runway to the launchpad. ??. Few Maxgambit 11/17/17 11:46:20 AM
#8   CTMX $41 price target fl89808 10/04/17 12:54:33 PM
#7   Up 35% after hours! fl89808 10/03/17 08:00:05 PM
#6   Enough cash in the bank until 2020 as fl89808 08/08/17 10:08:54 PM
#4   $200 million in the bank. No cash raises fl89808 06/04/17 10:18:27 AM
#3   "As of March 31, 2017, CytomX had cash, fl89808 05/05/17 10:10:17 AM
#2   Bristol-Myers Squibb Company BMY and CytomX Therapeutics, Inc. fl89808 03/21/17 08:05:26 PM
#1   $200M up front payment coming with 36.5 million fl89808 03/20/17 08:06:01 PM
PostSubject